

Nanocrystalline magnesium oxide: a novel and efficient catalyst for facile synthesis of 2,4,5-trisubstituted imidazole derivatives

Javad Safari · Shiva Dehghan Khalili ·
Mehran Rezaei · Sayed Hossein Banitaba ·
Fereshteh Meshkani

Received: 18 February 2010 / Accepted: 6 September 2010 / Published online: 7 October 2010
© Springer-Verlag 2010

Abstract Nanocrystalline magnesium oxide with high specific surface area has been used as a novel and efficient catalyst for an improved and rapid synthesis of biologically active 2,4,5-trisubstituted imidazoles, by three-component, one-pot condensation of 1,2-diketones and aryl aldehydes, in excellent yields under solvent-free and conventional heating conditions. The method has several advantages, for example excellent yields, shorter reaction time, and use of a non-toxic and recyclable catalyst.

Keywords Nanocrystalline magnesium oxide · 2,4,5-Trisubstituted imidazoles · One-pot condensation · Solvent-free conditions

Introduction


The synthesis, reactions, and biological properties of substituted imidazoles constitute a significant part of modern heterocyclic chemistry. Multi-substituted imidazoles, an important class of pharmaceutical compounds, have a wide spectrum of biological activity [1–3]. They have emerged as an integral part of many biological systems [4], viz. histidine, histamine, and biotin [5], and an

active backbone in drugs such as losartan, eprosartan [6], and trifenagrel [7]. They also have a variety of bioactive effects, for example fungicidal [8, 9], herbicidal [10], antitumor [11], anti-inflammatory [12], anti-allergic [13], analgesic [14], and antibacterial [15]. Some substituted imidazoles are selective antagonists of the glucagon receptor [16], inhibitors of p38 MAP kinase [17], B-Raf kinase [18], transforming growth factor β 1 (TGF- β 1) type 1 activin receptor-like kinase (ALK5) [19], cyclooxygenase-2 (COX-2) [20], and biosynthesis of interleukin-1 (IL-1) [21].

Several methods are used for synthesis of multi-substituted imidazoles [22–33]. Recently, one-pot condensations of an aldehyde and ammonium acetate with an α -hydroxy ketone, an α -keto oxime, or a 1,2-diketone have been achieved by using a variety catalysts, for example Zr(acac)₄ [34], Yb(OTf)₃ [35], Yb(OPf)₃ [36], InCl₃·3H₂O [37], I₂ [38], NiCl₂·6H₂O/Al₂O₃ [39], ZrCl₄ [40], silica sulfuric acid (SSA) [41, 42], boric acid [43], ionic liquids [44–47], heteropolyacid [48], ceric ammonium nitrate (CAN) [49, 50], sodium bisulfite [51], potassium aluminum sulfate (alum) [52], polymer-supported ZnCl₂ [53], phosphomolybdic acid [54], ZrOCl₂·8H₂O [55], L-proline [56], PEG-400 medium [57], and scolecite [58]. Despite their potential utility, some of these methods are not environmentally friendly and suffer from one or more disadvantages, for example hazardous reaction conditions, complex work-up and purification, strongly acidic conditions, high temperature, use of toxic metal catalysts, poor yields, occurrence of side reactions, and long reaction time. Therefore, the development of a mild general method to overcome these shortcomings remains a challenge for organic chemists in the synthesis of highly substituted imidazoles. Magnesium oxide (MgO) has many applications as catalyst [59, 60], refractory materials [61], optically transparent ceramic

J. Safari (✉) · S. D. Khalili · S. H. Banitaba
Laboratory of Organic Chemistry Research,
Department of Organic Chemistry, College of Chemistry,
University of Kashan, 87317-51167 Kashan, I.R. Iran
e-mail: Safari@kashanu.ac.ir

M. Rezaei · F. Meshkani
Catalyst and Advanced Materials Research Laboratory,
Chemical Engineering Department, Faculty of Engineering,
University of Kashan, 87317-51167 Kashan, I.R. Iran

**Scheme 1**

windows [62, 63], etc. Magnesium oxide with large specific surface area is also a potential catalyst support for various reactions and a promising sorbent for chemisorption and destructive adsorption of a variety of pollutants. In the field of catalysis, MgO has strongly basic properties, which are associated with catalysis by bases in many organic reactions [64]. Nanoscale supports create catalysts with more edges and corners, which can lead to higher performance of the catalyst. Herein, we report convenient and facile multi-component, one-pot synthesis of 2,4,5-trisubstituted imidazoles in high yields by using nanocrystalline magnesium oxide with high specific surface area of approximately $116 \text{ m}^2 \text{ g}^{-1}$ and a crystallite size of approximately 12 nm as a novel and efficient catalyst (Scheme 1).

Results and discussion

In an initial study, for examination of catalytic activity of different catalysts such as CaO, BaO, and MgO in this condensation reaction, 1 mmol benzaldehyde was first reacted with 1 mmol benzil and 2 mmol ammonium acetate for 30 min at 100 °C in the presence of each catalyst (2 mol%) separately. In the course of this study we found that MgO was the most effective catalyst (Table 1). In the absence of catalyst, yield of the product was found to be very low. Therefore, we decided to use nanocrystalline

MgO with a high specific surface area as a catalyst with higher activity and better controlled selectivity.


The crystallite sizes determined by XRD were between 12.8 and 17.5 nm (determined by use of the Scherrer equation), indicative of the nanocrystalline structure of the prepared MgO. In addition the surface area was approximately $116 \text{ m}^2 \text{ g}^{-1}$. The pore volume and pore size were also calculated from the N_2 adsorption result; the pore size was approximately 21.1 nm and the pore volume approximately $0.69 \text{ cm}^3 \text{ g}^{-1}$. The theoretical particle size was also calculated from surface area, assuming spherical particles, from the equation:

$$D_{BET} = \left(\frac{6,000}{\rho \times S} \right) \quad (1)$$

where D_{BET} is the equivalent particle diameter in nanometers, ρ is the density of the material in g cm^{-3} , and S is the specific surface area in $\text{m}^2 \text{ g}^{-1}$. The particle size calculated from Eq. 1 was 14.4 nm, which confirmed the nanostructure of the MgO sample [66]. The TEM image of MgO is shown in Fig. 1. As can be seen, the sample has a nanocrystalline structure with a plate-like shape.

Subsequent efforts were focused on optimizing conditions for formation of 2,4,5-triphenylimidazole by using different amounts of nanocrystalline MgO and different temperatures to determine their effects on the reaction (Table 2). As indicated, the best result was obtained at 100 °C with 5 mol% nanocrystalline MgO. The reaction yield with increasing amount of nanocrystalline MgO and temperature was not substantially increased.

Results from nanocrystalline magnesium oxide-catalyzed condensation reaction of 1,2-diketones (benzil, **1a**, 4,4'-difluorobenzil, **1b**) with different aromatic aldehydes and ammonium acetate at 100 °C under solvent-free conditions are given in Table 3. As shown, these conditions proved to be general for the reacting aldehyde. Aldehydes bearing either electron-withdrawing or electron-donating

Table 1 Synthesis of 2,4,5-triphenyl-1*H*-imidazole in the presence of metal oxide catalysts

Entry	Catalyst	Time (min)	Temperature (°C)	Yield (%)
1	None	30	100	15
2	MgO	30	100	55
3	CaO	30	100	20
4	BaO	30	100	50
5	Nano-MgO	30	100	80



**Fig. 1** TEM image of nanocrystalline MgO

Table 2 Optimization of reaction conditions for synthesis of 2,4,5-triphenyl-1*H*-imidazole

Entry	Nanocrystalline MgO (mol%)	Temperature (°C)	Time (min)	Yield (%)
1	2	60	30	35
2	5	60	30	50
3	7	60	30	55
4	11	60	30	55
5	2	100	30	80
6	5	100	30	94
7	7	100	30	93
8	11	100	30	92
9	2	130	30	80
10	5	130	30	95
11	7	130	30	92
12	11	130	30	92

groups perform equally well in the reaction and all imidazoles were obtained in high yields.

The high efficiency of the nanoparticle oxides is caused not only by their high surface area but also by the high concentration of low-coordinated sites and structural defects on their surface. As the particle size is scaled down to a few nanometers, the constituting atoms have highly defective coordination environments. Most of the atoms have unsatisfied valencies and reside at the surface [65]. Nanocrystalline MgO also acts as a mild Lewis acid that catalyzes three-component, one-pot synthesis of 2,4,5-trisubstituted imidazoles.

The structure of compounds **4a–4v** was deduced from their high-field ^1H NMR, ^{13}C NMR, IR, and UV spectral data. Also, their melting points were compared with literature reports. The ^1H NMR spectra of all the products contained a singlet at approximately $\delta = 12.50\text{--}12.80$ ppm. IR spectra contained a distinguishing peak at $3,400\text{--}3,440\text{ cm}^{-1}$ for NH. In ^{13}C NMR spectra of fluorinated derivatives, C–F couplings were observed with coupling constants of $^1J_{\text{C}-\text{F}} = 241\text{--}244$ Hz, $^2J_{\text{C}-\text{F}} = 21\text{--}22$ Hz, $^3J_{\text{C}-\text{F}} = 7\text{--}8$ Hz, and $^4J_{\text{C}-\text{F}} = 2$ Hz. For example, the ^{13}C NMR spectrum of compound **4t** is indicated in Fig. 2.

In summary, we describe a facile, eco-friendly, and green procedure for synthesis of biologically active 2,4,5-trisubstituted imidazoles via condensation of representative 1,2-diketones with a variety of aromatic aldehydes and ammonium acetate in the presence of nanocrystalline

magnesium oxide with high surface area as a novel, efficient, and recyclable catalyst under solvent-free and conventional heating conditions. The approach has several benefits, for example low waste, easy work up, short reaction time, and high yields.

Experimental

Materials


Chemical reagents in high purity were purchased from the Merck Chemical Company. All materials were of commercial reagent grade.

Apparatus

Melting points were determined in open capillaries using an Electrothermal Mk3 apparatus. Infrared spectra were recorded using a Perkin–Elmer FTIR 550 spectrometer. ^1H NMR and ^{13}C NMR spectra were recorded with a Bruker DRX-400 spectrometer at 400 and 100 MHz, respectively. NMR spectra were obtained in $\text{DMSO}-d_6$ solutions and are reported as parts per million (ppm) downfield from tetramethylsilane as internal standard. The abbreviations used are: singlet (s), doublet (d), triplet (t), and multiplet (m). Elemental analysis (C, H, N) was performed with a Carlo Erba model EA 1108 analyzer or a Perkin–Elmer 240c analyzer, and results agreed favorably with calculated values. UV spectra were recorded on a Hitachi 200-20 spectrophotometer using spectrophotometric grade chloroform (Baker). The N_2 adsorption/desorption analysis (BET) was performed at $-196\text{ }^\circ\text{C}$ using an automated gas adsorption analyzer (Tristar 3000, Micromeritics). XRD analysis was performed with an X-ray diffractometer (PANalytical X’Pert-Pro) using a $\text{Cu-K}\alpha$ monochromatic radiation source and an Ni filter. Transmission electron microscopy (TEM) was performed with a Jeol JEM-2100UHR, operated at 200 kV.


Preparation of nanocrystalline MgO

Nanocrystalline MgO was prepared by means of a procedure reported elsewhere [66]. In short, poly(vinyl alcohol) (PVA, MW 70,000) was dissolved in water at $90\text{ }^\circ\text{C}$ under vigorous stirring to form a transparent solution. $\text{Mg}(\text{NO}_3)_2 \cdot 6\text{H}_2\text{O}$ was dissolved in water containing PVA. The metal ion-to-PVA monomer unit molar ratio (M/PVA) was chosen as 1:3. Aqueous ammonia (25% w/w) was added dropwise at room temperature to the resulting viscous liquid mixture, with rapid stirring, to achieve careful pH adjustment to 10.5. After precipitation, the slurry was stirred for another 30 min and then heated under reflux at $80\text{ }^\circ\text{C}$ for 20 h under continuous

Table 3 Nanocrystalline MgO-catalyzed synthesis of 2,4,5-trisubstituted imidazoles at 100 °C under solvent-free conditions

Entry	Benzil	Ar ¹ , Ar ²	Aldehyde	Ar ³	Product	Yield (%) ^a Time (min)	M.p. (°C)	
							Found	Reported
1	1a	C ₆ H ₅	3a	C ₆ H ₅	4a	94 (30)	270–272	272–273 [38]
2	1a	C ₆ H ₅	3b	p-MeC ₆ H ₄	4b	96 (30)	230–233	232–235 [12]
3	1a	C ₆ H ₅	3c	p-MeOC ₆ H ₄	4c	97 (30)	228–231	230–232 [12]
4	1a	C ₆ H ₅	3d	p-ClC ₆ H ₄	4d	94 (30)	260–261	262–264 [12]
5	1a	C ₆ H ₅	3e	p-BrC ₆ H ₄	4e	93 (30)	263–265	261.5–263.5 [12]
6	1a	C ₆ H ₅	3f	m-MeOC ₆ H ₄	4f	93 (30)	259–262	–
7	1a	C ₆ H ₅	3g	O-HOC ₆ H ₄	4g	91 (30)	198–201	203–205 [38]
8	1a	C ₆ H ₅	3h	m-O ₂ NC ₆ H ₄	4h	90 (30)	269–271	265–267 [38]
9	1a	C ₆ H ₅	3i	m-ClC ₆ H ₄	4i	91 (30)	282–283	285–287 [12]
10	1a	C ₆ H ₅	3j	m-BrC ₆ H ₄	4j	92 (30)	301–303	303–304 [12]
11	1a	C ₆ H ₅	3k	p-HOC ₆ H ₄	4k	95 (30)	259–260	260–261 [38]
12	1a	C ₆ H ₅	3l	2-Naphthyl	4l	94 (30)	273–276	–
13	1a	C ₆ H ₅	3m	2-Thienyl	4m	94 (30)	261–264	262–266 [12]
14	1a	C ₆ H ₅	3n	2,4-Cl ₂ C ₆ H ₃	4n	92 (30)	170–172	174–176 [12]
15	1a	C ₆ H ₅	3o	p-(Me) ₂ NC ₆ H ₄	4o	93 (30)	255–257	257–258 [35]
16	1a	C ₆ H ₅	3p	3,4-(MeO) ₂ C ₆ H ₃	4p	94 (30)	213–216	215–219 [12]
17	1a	C ₆ H ₅	3q	3,5-(MeO) ₂ C ₆ H ₃	4q	94 (30)	254–256	–
18	1a	C ₆ H ₅	3r	3-HO-4-MeOC ₆ H ₄	4r	96 (30)	215–216	–
19	1b	4-F C ₆ H ₅	3f	m-MeOC ₆ H ₄	4s	94 (30)	251–253	–
20	1b	4-F C ₆ H ₅	3j	m-BrC ₆ H ₄	4t	95 (30)	287–290	–
21	1b	4-F C ₆ H ₅	3p	3,4-(MeO) ₂ C ₆ H ₃	4u	96 (30)	207–208	–
22	1b	4-F C ₆ H ₅	3r	3-HO-4-MeOC ₆ H ₄	4v	97 (30)	218–220	–

^a Isolated yield based on aldehyde

**Fig. 2** ¹³C NMR spectrum of compound **4t**

stirring. The mixture was cooled to room temperature, filtered, and washed with hot deionized water for effective removal of the poly(vinyl alcohol). The final product was dried at 80 °C for 24 h and calcined at 700 °C.

Preparation of 2,4,5-trisubstituted imidazoles by use of nanocrystalline magnesium oxide

A mixture of 1,2-diketone (1 mmol), 0.15 g ammonium acetate (2 mmol), aldehyde (1 mmol), and 0.008 g nanocrystalline magnesium oxide (5 mol%) was stirred at 100 °C for 30 min. The progress of the reaction was monitored by TLC (petroleum ether–ethyl acetate 7:3). After cooling, the reaction mixture was dissolved in acetone and filtered. The filtrate was concentrated on a rotary evaporator under reduced pressure and the solid product obtained was washed with water and recrystallized from acetone–water 9:1 (v/v). Pure products were obtained in excellent yields, as summarized in Table 3. Most of the products are known and were identified by comparison of their physical and spectral data with those of authentic samples.

2-(3-Methoxyphenyl)-4,5-diphenyl-1*H*-imidazole**(4f**, C₂₂H₁₈N₂O)

Colorless powder; yield 93%; m.p.: 259–262 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.70 (s, 1H, NH), 6.80–7.80 (m, 14H, Ar–H), 3.80 (s, 3H, OMe) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 160.00, 145.86, 137.63, 135.60, 132.15, 130.27, 129.20, 128.86, 127.70, 118.13, 114.70, 110.70, 55.70 ppm; IR (KBr): ̄ = 3,432 (N–H), 1,591 (C=C), 1,513 (C=N) cm^{−1}; UV (CDCl₃): λ_{max} = 314, 240 nm.

2-(2-Naphthyl)-4,5-diphenyl-1*H*-imidazole**(4l**, C₂₅H₁₈N₂)

Colorless powder; yield 94%; m.p.: 273–276 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.80 (s, 1H, NH), 8.61 (s, 1H, Ar–H), 8.25 (d, 1H, ³J = 8.0 Hz, Ar–H), 7.92–8.02 (m, 3H, Ar–H), 7.53–7.61 (m, 6H, Ar–H), 7.46 (t, 2H, ³J = 7.9 Hz, Ar–H), 7.39 (t, 1H, ³J = 7.6 Hz, Ar–H), 7.32 (t, 2H, ³J = 7.9 Hz, Ar–H), 7.24 (t, 1H, ³J = 7.6 Hz, Ar–H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 146.00, 137.90, 135.60, 133.50, 132.20, 131.50, 129.10, 129.00, 128.90, 128.70, 128.60, 128.30, 128.20, 127.60, 127.10, 127.00, 126.80, 124.10, 123.90 ppm; IR (KBr): ̄ = 3,429 (N–H), 1,601 (C=C), 1,510 (C=N) cm^{−1}; UV (CDCl₃): λ_{max} = 330, 288 nm.

2-(3,5-Dimethoxyphenyl)-4,5-diphenyl-1*H*-imidazole**(4q**, C₂₃H₂₀N₂O₂)

Colorless powder; yield 94%; m.p.: 254–256 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.70 (s, 1H, NH), 7.30–7.54 (m, 9H, Ar–H), 7.28 (d, 2H, ⁴J = 2.0 Hz, Ar–H), 7.22 (t, 1H, ³J = 7.8 Hz, Ar–H), 6.52 (t, 1H, ⁴J = 2.0 Hz, Ar–H), 3.81 (s, 6H, OMe) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 161.21, 145.76, 137.51, 135.56, 132.59, 131.52, 129.14, 128.98, 128.65, 128.30, 127.56, 127.01, 103.54, 101.10, 55.83 ppm; IR (KBr): ̄ = 3,429 (N–H), 1,601 (C=C), 1,533 (C=N) cm^{−1}; UV (CDCl₃): λ_{max} = 310, 245 nm.

5-(4,5-Diphenyl-1*H*-imidazol-2-yl)-2-methoxyphenol**(4r**, C₂₂H₁₈N₂O₂)

Ash-gray powder; yield 96%; m.p.: 215–216 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.50 (s, 1H, NH), 9.11 (s, 1H, OH), 7.46–7.55 (m, 6H, Ar–H), 7.42 (t, 2H, ³J = 7.6 Hz, Ar–H), 7.34 (t, 1H, ³J = 7.2 Hz, Ar–H), 7.28 (t, 2H, ³J = 7.6 Hz, Ar–H), 7.20 (t, 1H, ³J = 7.2 Hz, Ar–H), 7.00 (d, 1H, ³J = 8.4 Hz, Ar–H), 3.81 (s, 3H, OMe) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 148.58, 146.99, 146.31, 137.17, 135.86, 131.71, 129.05, 128.82, 128.62, 128.02, 127.51, 126.84, 123.94, 117.01, 113.31, 112.55, 56.09 ppm; IR (KBr): ̄ = 3,409 (N–H), 3,260 (O–H), 1,596 (C=C), 1,510 (C=N) cm^{−1}; UV (CDCl₃): λ_{max} = 310, 244 nm.

2-(3-Methoxyphenyl)-4,5-bis(4-fluorophenyl)-1*H*-imidazole (4s**, C₂₂H₁₆F₂N₂O)**

Off-white powder; yield 94%; m.p.: 251–253 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.71 (s, 1H, NH), 7.65 (d, 1H, ³J = 7.6 Hz, Ar–H), 7.62 (s, 1H, Ar–H), 7.50–7.55 (m, 4H, Ar–H), 7.38 (t, 1H, ³J = 8.0 Hz, Ar–H), 7.30 (t, 2H, ³J = 8.8 Hz, Ar–H), 7.15 (t, 2H, ³J = 8.8 Hz, Ar–H), 6.94 (d, 1H, ³J = 8.0 Hz, Ar–H), 3.82 (s, 3H, OMe) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 162.20 (C–F, d, ¹J = 243.0 Hz), 161.57 (C–F, d, ¹J = 243.0 Hz), 160.05, 145.90, 136.74, 132.04, 131.94, 131.09 (d, ³J = 7.0 Hz), 130.26, 129.37 (d, ³J = 7.0 Hz), 127.83, 127.58, 118.11, 116.15 (d, ²J = 21.0 Hz), 115.56 (d, ²J = 22.0 Hz), 114.68, 110.74, 55.61 ppm; IR (KBr): ̄ = 3,441 (N–H), 1,600 (C=C), 1,520 (C=N) cm^{−1}; UV (CDCl₃): λ_{max} = 315, 245 nm.

2-(3-Bromophenyl)-4,5-bis(4-fluorophenyl)-1*H*-imidazole (4t**, C₂₁H₁₃BrF₂N₂)**

Colorless powder; yield 95%; m.p.: 287–290 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.70 (s, 1H, NH), 8.26 (s, 1H, Ar–H), 8.06 (d, 1H, ³J = 8.0 Hz, Ar–H), 7.52–7.55 (m, 5H, Ar–H), 7.44 (t, 1H, ³J = 8.0 Hz, Ar–H), 7.30 (t, 2H, ³J = 8.4 Hz, Ar–H), 7.15 (t, 2H, ³J = 8.4 Hz, Ar–H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 162.25 (C–F, d, ¹J = 244.0 Hz), 161.62 (C–F, d, ¹J = 242.0 Hz), 144.34, 137.01, 132.85, 131.69 (d, ⁴J = 2.0 Hz), 131.37 (d, ³J = 8.0 Hz), 131.09, 131.01, 129.42 (d, ³J = 8.0 Hz), 128.09, 127.98, 127.56 (d, ⁴J = 2.0 Hz), 124.50, 122.62, 116.22 (d, ²J = 22.0 Hz), 115.64 (d, ²J = 21.0 Hz) ppm; IR (KBr): ̄ = 3,437 (N–H), 1,604 (C=C), 1,516 (C=N) cm^{−1}; UV (CDCl₃): λ_{max} = 310, 245 nm.

2-(3,4-Dimethoxyphenyl)-4,5-bis(4-fluorophenyl)-1*H*-imidazole (4u**, C₂₃H₁₈F₂N₂O₂)**

Off-white powder; yield 96%; m.p.: 207–208 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.50 (s, 1H, NH), 7.48–7.63 (m, 6H, Ar–H), 7.30 (t, 2H, ³J = 8.0 Hz, Ar–H), 7.14 (t, 2H, ³J = 8.0 Hz, Ar–H), 7.05 (d, 1H, ³J = 8.0 Hz, Ar–H), 3.80 (s, 3H, OMe), 3.83 (s, 3H, OMe) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 162.11 (C–F, d, ¹J = 243.0 Hz), 161.47 (C–F, d, ¹J = 241.0 Hz), 149.59, 149.27, 146.17, 136.36, 132.04, 131.06 (d, ³J = 8.0 Hz), 129.30 (d, ³J = 8.0 Hz), 128.02, 127.00, 123.55, 118.38, 116.18 (d, ²J = 21.0 Hz), 115.56 (d, ²J = 21.0 Hz), 112.27, 109.26, 56.03, 55.98 ppm; IR (KBr): ̄ = 3,424 (N–H), 1,599 (C=C), 1,524 (C=N) cm^{−1}; UV (CDCl₃): λ_{max} = 310, 243 nm.

5-[4,5-Bis(4-fluorophenyl)-1*H*-imidazol-2-yl]-2-methoxyphenol (4v**, C₂₂H₁₆F₂N₂O₂)**

Silver powder; yield 97%; m.p.: 218–220 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.50 (s, 1H, NH), 9.13 (s, 1H, OH), 7.40–7.60 (m, 6H, Ar–H), 7.27 (t, 2H,

$^3J = 8.8$ Hz, Ar–H), 7.13 (t, 2H, $^3J = 8.8$ Hz, Ar–H), 7.00 (d, 1H, $^3J = 8.4$ Hz, Ar–H), 3.81 (s, 3H, OMe) ppm; ^{13}C NMR (100 MHz, DMSO- d_6): $\delta = 162.06$ (C–F, d, $^1J = 244.0$ Hz), 161.47 (C–F, d, $^1J = 242.0$ Hz), 148.66, 147.02, 146.34, 136.32, 132.17, 130.96 (d, $^3J = 8.0$ Hz), 129.31 (d, $^3J = 8.0$ Hz), 128.00, 126.91, 123.84, 117.05, 116.08 (d, $^2J = 21.0$ Hz), 115.53 (d, $^2J = 21.0$ Hz), 113.32, 112.56, 56.08 ppm; IR (KBr): $\bar{\nu} = 3,437$ (N–H), 3,298 (O–H), 1,594 (C=C), 1,521 (C=N) cm^{-1} ; UV (CDCl_3): $\lambda_{\text{max}} = 310, 242$ nm.

Acknowledgments We gratefully acknowledge the financial support from the Research Council of the University of Kashan.

References

- Lombardino JG, Wiseman EH (1974) *J Med Chem* 17:1182
- Heeres J, Back LJJ, Mostmans JH, Vancutsem J (1979) *J Med Chem* 22:1003
- Mjalli AMM, Sarshar S (1997) US Patent 570082619 (1998) *Chem Abstr* 128 88918a
- Laufer SA, Zimmermann W, Ruff KJ (2004) *J Med Chem* 47:6311
- Grimmett MR (1996) In: Katritzky AR, Rees CW, Scriven EFV (eds) Comprehensive heterocyclic chemistry II, Pergamon Press, Oxford, vol 3, p 77
- Kantevari S, Nair CKS, Pardhasaradhi M (2006) *J Heterocycl Chem* 43:1353
- Wolkenberg SE, Wisnoski DD, Leister WH, Wang Y, Zhao Z, Lindsley CW (2004) *Org Lett* 6:1453
- Pozherskii AF, Soldatenkov AT, Kareizky AR (1997) *Heterocycles in life and society*. Wiley, New York, p 179
- Maier T, Schmierer R, Bauer K, Bieringer H, Buerstell H, Sachse B (1989) US Patent 4820335
- Liebl R, Handte R, Mildenberger H, Bauer K, Bieringer H (1987) Ger Offen DE 3604042
- Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, Gherke L, Credo RB, Hui YH, Marsh K, Warner R, Lee JY, Zielinsky-Mozng N, Frost D, Rosenberg SH, Sham HL (2002) *J Med Chem* 45:1697
- Lombardino JG (1972) DE 2155558 [(1973) US 3772441]
- Black JW, Durant GJ, Emmett JC, Ganellin CR (1974) *Nature* 248:65
- Ucucu U, Karaburun NG, Iskdag I (2001) *Il Farmaco* 56:285
- Khan MS, Siddiqui SA, Siddiqui MSR, Goswami U, Srinivasan KV, Khan MI (2008) *Chem Biol Drug Des* 72:197
- Chang LL, Sidler KL, Cascieri MA, Laszlo SD, Koch G, Li B, MacCoss M, Mantlo N, O'Keefe S, Pang M, Rolando A, Hagemann WK (2001) *Bioorg Med Chem Lett* 11:2549
- Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Vatter SWL, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR (1994) *Nature* 372:739
- Takle AK, Brown MJB, Davies S, Dean DK, Francis G, Gaiba A, Hird AW, King FD, Lovell PJ, Naylor A, Reith AD, Steadman JG, Wilson DM (2006) *Bioorg Med Chem Lett* 16:378
- Khanna IK, Weier RM, Yu Y, Xu XD, Koszyk FJ, Collins PW, Koboldt CM, Veenhuizen AW, Perkins WE, Casler JJ, Masferrer JL, Zhang YY, Gregory SA, Seibert K, Isakson PC (1997) *J Med Chem* 40:1634
- Lange JHM, Van Stuivenberg HH, Coolen HKAC, Adolfs TJP, McCreary AC, Keizer HG, Wals HC, Veerman W, Borst AJM, de Looff W, Verveer PC, Kruse CG (2005) *J Med Chem* 48:1823
- Gallagher TH, Fier-Thompson SM, Garigipati RS, Sorenson ME, Smietana JM, Lee D, Bender PE, Lee JC, Laydon JT, Griswold DE, Chabot-Fletcher MC, Breton JJ, Adams JL (1995) *Bioorg Med Chem Lett* 5:1171
- Sparks RB, Combs AP (2004) *Org Lett* 6:2473
- Zaman S, Mitsuru K, Abell AD (2005) *Org Lett* 7:609
- Tsuji J, Sakai K, Nemoto H, Nagashima H (1983) *J Mol Catal* 18:169
- Evans DA, Lundy KM (1992) *J Am Chem Soc* 114:1495
- Radziszewski B (1882) *Ber Deut Chem Ges* 15:1493
- Wasserman HH, Long YO, Zhang R, Parr J (2002) *Tetrahedron Lett* 43:3351
- Kamitori Y (2001) *J Heterocycl Chem* 38:773
- Zhang C, Moran EJ, Woiwade TF, Short KM, Mjalli AMM (1996) *Tetrahedron Lett* 37:751
- Lantos I, Zhang WY, Shui Y, Eggleston DS (1993) *J Org Chem* 58:7092
- Bleicher KH, Gerber F, Wuthrich Y, Alanine A, Capretta A (2002) *Tetrahedron Lett* 43:7687
- Balalaie S, Hashemi MM, Akhbari M (2003) *Tetrahedron Lett* 44:1709
- Paone DV, Shaw AW (2008) *Tetrahedron Lett* 49:6155
- Khosropour AR (2008) *Ultrasound Sonochem* 15:659
- Wang L, Wang Y, Tian H, Yao Y, Shao J, Liu B (2006) *J Fluorine Chem* 127:1570
- Shen M, Cai C, Yi W (2008) *J Fluorine Chem* 129:541
- Sharma SD, Hazarika P, Konwar D (2008) *Tetrahedron Lett* 49:2216
- Kidwai M, Mothsra P, Bansal V, Somvanshi RK, Ethayathulla AS, Dey S, Singh TP (2007) *J Mol Catal A Chem* 265:177
- Heravi MM, Bakhtiari K, Oskooie HA, Taheri S (2007) *J Mol Catal A Chem* 263:279
- Sharma GVM, Jyothi Y, Sree Lakshmi P (2006) *Synth Commun* 36:2991
- Shaabani A, Rahmati A (2006) *J Mol Catal A Chem* 249:246
- Shaabani A, Rahmati A, Farhangi E, Badri Z (2007) *Catal Commun* 8:1149
- Shelke KF, Sapkal SB, Sonar SS, Madje BR, Shingate BB, Shingare MS (2009) *Bull Korean Chem Soc* 30:1057
- Siddiqui SA, Narkhede UC, Palimkar SS, Daniel T, Lahoti RJ, Srinivasan KV (2005) *Tetrahedron* 61:3539
- Xia M, Lu Y (2007) *J Mol Catal A Chem* 265:205
- Khosropour AR (2008) *Can J Chem* 86:264
- Chary MV, Keerthysri NC, Vupallapati S, Lingaiah N, Kantevari S (2008) *Catal Commun* 9:2013
- Karimi AR, Alimohammadi Z, Amini MM (2009) *Mol Diversity*. Accessed 29 October 2009
- Sangshetti JN, Kokare ND, Kotharkara SA, Shinde DB (2008) *J Chem Sci* 120:463
- Shaabani A, Maleki A, Behnam M (2009) *Synth Commun* 39:102
- Sangshetti JN, Shinde DB, Kokare ND, Kotharkar SA (2008) *Monatsh Chem* 139:125
- Mohamadi AA, Mivechi M, Kefayati H (2008) *Monatsh Chem* 139:935
- Wang L, Cai C (2009) *Monatsh Chem* 140:541
- Jadhave SD, Kokare ND, Jadhave SD (2009) *J Heterocycl Chem* 45:1461
- Sangshetti JN, Kokare ND, Kotharkar SA, Shinde DB (2008) *Chin Chem Lett* 19:762
- Samai S, Nandi GC, Singh P, Singh MS (2009) *Tetrahedron* 65:10155
- Wang XC, Gong HP, Quan ZJ, Li L, Ye HL (2009) *Chin Chem Lett* 20:44

58. Gadekar LS, Mane SR, Arbad BR, Katkar SS, Lande MK (2009) Cent Eur J Chem 7:550
59. Gulkova D, Solcova O, Zdrazil M (2004) Microporous Mesoporous Mater 76:137
60. Climent MJ, Corma A, Iborra S, Mifsud M (2007) J Catal 247:223
61. Faghihi-Sani MA, Yamaguchi A (2002) Ceram Int 28:835
62. Chaim R, Shen ZJ, Nygren MJ (2004) Mater Res 19:2527
63. Chen D, Jordan EH, Gell M (2008) Scr Mater 59:757
64. Hattori H (1995) Chem Rev 95:537
65. Meshkani F, Rezaei M (2010) Powder Technol 199:144
66. Meshkani F, Rezaei M (2009) Powder Technol 196:85